

THE SCIENTIFIC RATIONALE BEHIND 90-DAY FEEDING TRIAL REQUESTS

GMO NETWORK REPRESENTATIVES' PERSPECTIVES

WHY?

TO INFORM YOU WHERE WE ARE WITH THIS TOPIC

TO SEE HOW GRACE & G-TwYST HAS INFLUENCED THE OPINION
OF GMO NETWORK REPRESENTATIVES

TO INCREASE MUTUAL UNDERSTANDING ON THE SCIENTIFIC
NEED OF A 90-DAY FEEDING TRIAL

TO SHARE INFORMATION

OVERVIEW

1. **BACKGROUND & OVERVIEW OF OUTCOMES OF GRACE, G-TwYST, GMO 90+**
Gijs Kleter
2. **OVERVIEW OF GMO NETWORK PERSPECTIVES**
Adinda De Schrijver
3. **TOUR DE TABLE - Q&A - DISCUSSION**
everyone
4. **RAP-UP**

OUTCOMES EU & FRENCH PROJECTS

THREE MUTUALLY LINKED PROJECTS:

- **GRACE (EU)**
 - FEEDING TRIALS, DESK RESEARCH, IN-VITRO TOX & OMICS, CROP OMICS, CADIMA DATABASE
 - EU, 2012-2015, 7.8 M€, 19 PARTNERS, COORDINATOR JULIUS KÜHN INSTITUTE
 - REFERRED TO BY IMPLEMENTING REGULATION
- **G-TwYST (EU)**
 - FEEDING TRIALS, CROP OMICS
 - 2014-2018, 3.8 M€, 9 PARTNERS, COORDINATOR VETERINARY UNIVERSITY HANNOVER
- **GMO90+ (FR)**
 - FEEDING TRIALS, TOX-METABONOMICS, CROP ANALYSIS
 - 2014-2018, 3.7 M€, 10 PARTNERS, COORDINATOR TOXALIM
- **ALSO LINKAGES WITH OTHER PROJECTS, E.G. MARLON, PRESTO, AMIGA**
- **STAKEHOLDER INVOLVEMENT = IMPORTANT COMPONENT, E.G. WORKSHOPS, CONSULTATIONS**



OUTCOMES EU & FRENCH PROJECTS



Joint GRACE & G-TwYST recommendations (examples)

- Rat feeding studies with whole food/feed
 - Scientific value:
 - Chronic tests confirmed initial data and 90-d tests (no adverse effects)
 - No added value of adding immune function parameters to 90-d test
 - Necessity to perform a feeding trial should be carefully evaluated
 - *N.B. GMO90+ concurs: Value of the 90-day rodent study is limited without a specific hypothesis; it will not reduce scientific uncertainties*
- Design, conduct and analyses
 - E.g. number of animals vs. statistical power, historic references
 - Usefulness of patterns (instead of single endpoints) within chronic test results
- Compositional analysis (e.g. quality control)

OUTCOMES EU & FRENCH PROJECTS

GRACE:

- **OBJECTIVES**
 - **INFORMATION PROVISION (REVIEWS, 1-STOP SHOP), DATA GAPS, ASSESSMENT OF ADDED VALUE OF FEEDING TRIALS**
- **FEEDING TRIALS**
 - **MAIZE MON810 (GM, 2x), CONTROL, REFERENCE LINES**
 - **90-DAY & 1-YEAR, 0-11-33% INCLUSION RATE**
 - **ACCORDING TO EFSA & OECD GUIDELINES**
- **ADDITIONAL OMICS ANALYSES ON ANIMAL AND PLANT MATERIALS**
- **IN-VITRO TOXICITY TESTING**
- **WEBSITE [HTTP://WWW.GRACE-FP7.EU/](http://www.grace-fp7.eu/)**



OUTCOMES EU & FRENCH PROJECTS

GRACE:

- **OUTCOMES**
 - **FEEDING TRIALS: NO ADVERSE EFFECTS OBSERVED**
 - **VARIOUS DIFFERENCES OBSERVED WERE UNRELATED TO MON810**
 - **IN-VITRO TOX: NO EFFECTS OF MON810**
 - **E.G. EFFECTS OF CIRCADIAN RHYTHM DETECTED**
 - **CROP OMICS: NO IMPACTS OF GM (OTHER FACTORS INFLUENTIAL)**
 - **REVIEW/MAPPING OF EVIDENCE: NO NEW DATA IMPACTING ON FINDINGS**
- **RECOMMENDATIONS PUBLISHED JOINTLY WITH G-TwYST**



OUTCOMES EU & FRENCH PROJECTS

G-TwYST:

- **FEEDING TRIALS**
 - **NK603 MAIZE, TREATED/UNTREATED WITH GLYPHOSATE; & CONTROL**
 - **INCLUSION RATE 0-11-33% (PLUS 50% IN EXTRA 90-D TRIALS)**
 - **SUB-CHRONIC 90-DAY, CHRONIC 1-YEAR AND CARCINOGENICITY (2-YEAR)**
- **ADDITIONAL ANALYSES**
 - **CROP COMPOSITION & OMICS**
 - **ADDITIONAL CONSIDERATIONS, E.G., STATISTICS, INPUTS FROM LITERATURE, POINTS TO CONSIDER FOR DESIGN AND EXECUTION OF ANIMAL FEEDING TRIALS**
- **OUTCOMES**
 - **FEEDING TRIALS: NO ADVERSE EFFECTS OBSERVED**
 - **RECOMMENDATIONS ON JUSTIFICATION AND SCIENTIFIC VALUE**
 - **STUDIES PERFORMED IN ABSENCE OF HYPOTHESIS**
 - **NO BASIS FOR 90-DAY FEEDING TRIALS PROVIDED BY GRACE AND G-TWYST**
 - **NO VALUE OF EXTENSION TO LONG-TERM TRIALS**
 - **RECOMMENDATIONS DOCUMENT PUBLISHED JOINTLY WITH GRACE**
- **WEBSITE: [HTTPS://WWW.G-TWYST.EU/](https://www.g-twyst.eu/)**



OUTCOMES EU & FRENCH PROJECTS

GMO90+:



- FEEDING TRIALS
 - NK603 AND MON810 MAIZE; & CONTROL
 - INCLUSION RATE 0-11-33%
 - SUBCHRONIC 90-DAY, CHRONIC 0.5-YEAR
- ADDITIONAL ANALYSES:
 - TISSUE OMICS (METABOLOMICS ON FLUIDS, TRANSCRIPTOMICS ON LIVER & KIDNEY)
 - CROP COMPOSITION & OMICS
- OUTCOMES
 - FEEDING TRIALS: No adverse effects observed related to GM nature
 - Few differences observed could not be linked to absence of effects in biologically linked variables
 - Effects of maize variety and location of cultivation
 - No biomarker identified attributable to health effects of GMOs
- WEBSITE: [HTTP://RECHERCHE-RISKOOGM.FR/EN/PAGE/GMO90PLUS](http://RECHERCHE-RISKOOGM.FR/EN/PAGE/GMO90PLUS)

GMO NETWORK PERSPECTIVES

Scientific perspective on:

- 90-day feeding trials for single events
- (Re-)assessment of single events at the level of the 90-day feeding trial in the context of GM stacked events

QUESTIONNAIRE

1. Do you consider a 90-day feeding trial is only relevant on a case-by-case basis when a clear hypothesis for testing can be formulated? If not:
 - 1a. Please provide your scientific rationale for asking a 90-day feeding study for every application.
 - 1b. Did the outcome of the GRACE & G-TwYST project impact your point of view? Please explain briefly why this did or did not.
2. Do you consider that 90-day studies for single events previously positively assessed by EFSA, need to be re-assessed/re-conducted in the context of GM stacked events?

OUTCOME CONSULTATION

1. Do you consider a 90-day feeding trial is only relevant on a case-by-case basis when a clear hypothesis for testing can be formulated?

YES: GMO Network representatives from 20 European countries

NO: GMO Network representatives from 5 European countries

?: GMO Network representatives from 6 European countries

2. Do you consider that 90-day studies for single events previously positively assessed by EFSA, need to be re-assessed/re-conducted in the context of GM stacked events?

YES: -

NO: GMO Network representatives from 21 European countries

OUTCOME CONSULTATION

1a. Please provide your scientific rationale for asking a 90-day feeding study for every application.

Reply: *90-day feeding trial can provide answers*

Reply: *due to the limited number of compounds tested during compositional assessment, identification of unintended effects is not always possible. This uncertainty may be overcome by a 90-day feeding trial.*

1b. Did the outcome of the GRACE & G-TwYST project impact your point of view? Please explain briefly why this did or did not.

Reply: *outcome of GRACE & G-TwYST does not allow to go for case-by-case, as a feeding trial with one GM crop is not sufficient to conclude what can happen with another*

Reply: *GRACE project did not due to inadequacies in final report*

TOUR DE TABLE - Q&A - DISCUSSION



RAP-UP

“ The current uncertainties in relation to the need and design of 90-day feeding trials will be addressed by a large research project under the ... FP7 ... The requirements ... should be reviewed in the light of this project ... (IR 503/2013)”

